Literature DB >> 23247100

Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.

Jun Mimuro1, Hiroaki Mizukami, Shuji Hishikawa, Tomokazu Ikemoto, Akira Ishiwata, Asuka Sakata, Tsukasa Ohmori, Seiji Madoiwa, Fumiko Ono, Keiya Ozawa, Yoichi Sakata.   

Abstract

Neutralizing antibodies (NAbs) against adeno-associated viruses (AAVs) are known to interfere with AAV vector-mediated gene transfer by intravascular delivery. Evading the inhibitory effects of antibodies against AAV vectors is necessary for efficient transfer of therapeutic genes clinically. For this purpose, we tested the efficacy of saline flushing in order to avoid contact of vectors with NAbs present in blood. Direct injection of the AAV8 vector carrying the factor IX (FIX) gene into the portal vein of macaques using saline flushing achieved transgene-derived FIX expression (4.7 ± 2.10-10.1 ± 5.45% of normal human FIX concentration) in the presence of NAbs. Expression was as efficient as that (5.43 ± 2.59-12.68 ± 4.83%) in macaques lacking NAbs. We next tested the efficacy of saline flushing using less invasive balloon catheter-guided injection. This approach also resulted in efficient expression of transgene-derived FIX (2.5 ± 1.06-9.0 ± 2.37%) in the presence of NAbs (14-56× dilutions). NAbs at this range of titers reduced the efficiency of transduction in the macaque liver by 100-fold when the same vector was injected into mesenteric veins without balloon catheters. Our results suggest that portal vein-directed vector delivery strategies with flushing to remove blood are efficacious for minimizing the inhibitory effect of anti-AAV antibodies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23247100      PMCID: PMC3594013          DOI: 10.1038/mt.2012.258

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  35 in total

1.  Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.

Authors:  M Moskalenko; L Chen; M van Roey; B A Donahue; R O Snyder; J G McArthur; S D Patel
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line.

Authors:  Elham S Mohammadi; Elizabeth A Ketner; David C Johns; Gary Ketner
Journal:  Nucleic Acids Res       Date:  2004-05-11       Impact factor: 16.971

3.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

4.  Cardiorespiratory effects of rapid saline infusion in normal man.

Authors:  A L Muir; D C Flenley; B J Kirby; M F Sudlow; A R Guyatt; H M Brash
Journal:  J Appl Physiol       Date:  1975-05       Impact factor: 3.531

5.  Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.

Authors:  C Li; N Narkbunnam; R J Samulski; A Asokan; G Hu; L J Jacobson; M J Manco-Johnson; P E Monahan
Journal:  Gene Ther       Date:  2011-06-23       Impact factor: 5.250

6.  Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

Authors:  Amit C Nathwani; Cecilia Rosales; Jenny McIntosh; Ghasem Rastegarlari; Devhrut Nathwani; Deepak Raj; Sushmita Nawathe; Simon N Waddington; Roderick Bronson; Scott Jackson; Robert E Donahue; Katherine A High; Federico Mingozzi; Catherine Y C Ng; Junfang Zhou; Yunyu Spence; M Beth McCarville; Marc Valentine; James Allay; John Coleman; Susan Sleep; John T Gray; Arthur W Nienhuis; Andrew M Davidoff
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

Review 7.  Preclinical and clinical gene therapy for haemophilia.

Authors:  M K L Chuah; D Collen; T Vandendriessche
Journal:  Haemophilia       Date:  2004-10       Impact factor: 4.287

8.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Authors:  Catherine S Manno; Amy J Chew; Sylvia Hutchison; Peter J Larson; Roland W Herzog; Valder R Arruda; Shing Jen Tai; Margaret V Ragni; Arthur Thompson; Margareth Ozelo; Linda B Couto; Debra G B Leonard; Frederick A Johnson; Alan McClelland; Ciaran Scallan; Erik Skarsgard; Alan W Flake; Mark A Kay; Katherine A High; Bertil Glader
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

Review 9.  AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.

Authors:  N C Hasbrouck; K A High
Journal:  Gene Ther       Date:  2008-04-24       Impact factor: 5.250

10.  Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.

Authors:  Amit C Nathwani; John T Gray; Jenny McIntosh; Catherine Y C Ng; Junfang Zhou; Yunyu Spence; Melanie Cochrane; Elaine Gray; Edward G D Tuddenham; Andrew M Davidoff
Journal:  Blood       Date:  2006-11-07       Impact factor: 22.113

View more
  29 in total

Review 1.  The potential of adeno-associated viral vectors for gene delivery to muscle tissue.

Authors:  Dan Wang; Li Zhong; M Abu Nahid; Guangping Gao
Journal:  Expert Opin Drug Deliv       Date:  2014-01-03       Impact factor: 6.648

2.  Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors.

Authors:  Brad E Hoffman; Roland W Herzog
Journal:  Mol Ther       Date:  2013-09       Impact factor: 11.454

Review 3.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

4.  Flushing out antibodies to make AAV gene therapy available to more patients.

Authors:  Steven E Raper; James M Wilson; Frederick A Nunes
Journal:  Mol Ther       Date:  2013-02       Impact factor: 11.454

Review 5.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

Review 6.  Adeno-associated viral vectors for the treatment of hemophilia.

Authors:  Katherine A High; Xavier M Anguela
Journal:  Hum Mol Genet       Date:  2015-11-27       Impact factor: 6.150

Review 7.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

8.  Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer.

Authors:  Chengwen Li; Shuqing Wu; Blake Albright; Matthew Hirsch; Wuping Li; Yu-Shan Tseng; Mavis Agbandje-McKenna; Scott McPhee; Aravind Asokan; R Jude Samulski
Journal:  Mol Ther       Date:  2015-07-29       Impact factor: 11.454

Review 9.  Advances in gene therapy for hemophilia: basis, current status, and future perspectives.

Authors:  Tsukasa Ohmori
Journal:  Int J Hematol       Date:  2018-08-06       Impact factor: 2.490

10.  Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo.

Authors:  Bence György; Zachary Fitzpatrick; Matheus H W Crommentuijn; Dakai Mu; Casey A Maguire
Journal:  Biomaterials       Date:  2014-06-07       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.